VA clinic closed June 19 for Juneteenth — DAV services moved to 26th
Because the Hagerstown Community Based Outpatient Clinic will be closed June 19 for the Juneteenth holiday, the Disabled American Veterans service officer has rescheduled his availability to Thursday, June 26, according to a community announcement.
The DAV Service Officer assists with VA claims for service members, veterans and their families. To schedule an appointment, call Ernie Unger at 301-842-2562 or 301-331-0091, or send an email to michelobqt@yahoo.com.
This story was created by Janis Reeser, jreeser@gannett.com, with the assistance of Artificial Intelligence (AI). Journalists were involved in every step of the information gathering, review, editing and publishing process. Learn more at cm.usatoday.com/ethical-conduct or share your thoughts at http://bit.ly/3RapUkA with our News Automation and AI team.
The Herald-Mail is growing its local news: Send your news to us
This article originally appeared on The Herald-Mail: Juneteenth holiday shifts DAV services in Hagerstown to June 26
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Rare Yet Alarming: US Study Maps Syphilitic Uveitis Trends
Between 2013 and 2024, syphilitic uveitis remained a rare but serious manifestation of syphilis in the United States, predominantly affecting men, older individuals, and patients with concurrent HIV, and frequently resulting in low vision and blindness. METHODOLOGY: Researchers analyzed data from a national clinical database to determine the incidence and prevalence of syphilitic uveitis in the United States, as well as the rates of sexually transmitted coinfections and associated ocular complications. Participants with syphilitic uveitis were identified using diagnostic codes for uveitis and positive treponemal and nontreponemal test for syphilis obtained within 1 month of a diagnosis of uveitis. Data collection included demographic information and rates of concurrent sexually transmitted infections, including HIV, gonorrhea, and chlamydia; these infections were recorded if diagnosed at the time of, or within 1 month after, a diagnosis of uveitis. Ocular complications included macular edema and low vision or blindness, identified at the time of a diagnosis of uveitis or within 6 months thereafter. TAKEAWAY: The researchers identified 161,317 cases of syphilis and 237 cases of syphilitic uveitis; from 2013 to 2024, the cumulative incidence and prevalence rates of syphilitic uveitis were 0.36 and 0.27 per 100,000 individuals, respectively, with both incidence and prevalence increasing over this period. Compared with the general population in the same database, patients with syphilitic uveitis were more likely to be men and older. HIV was the most common concurrent sexually transmitted infection, occurring in 32.49% of cases; gonorrhea and chlamydia occurred less frequently, at 4.22%. The most common complication was low vision or blindness, occurring predominantly in patients with panuveitis or posterior uveitis. IN PRACTICE: 'Our findings reinforce the need for ordering syphilis testing at uveitis presentation and the prompt initiation of intravenous antibiotic therapy thereafter to prevent irreversible ocular damage,' the researchers wrote. SOURCE: The study was led by Lucy Ruoxi Zhou, of the Drexel University College of Medicine in Philadelphia. It was published online on June 4, 2025, in the American Journal of Ophthalmology . LIMITATIONS: The reliance on electronic health record databases may have introduced coding variability and inaccuracies. The requirement for syphilis testing to occur within 1 month after a diagnosis of uveitis potentially excluded patients tested before or on the same day as their diagnosis or those experiencing diagnostic delays longer than 1 month. This study could not assess prescribed treatments and changes in clinical endpoints, including improvement in vision or resolution of macular edema after treatment. DISCLOSURES: One author received support from the Hankins and Dracopoulos Uveitis Research Funds.
Associated Press
an hour ago
- Associated Press
Veritas Veterinary Partners Advances Strategic Growth Plan with Key Investments and Executive Appointments
TINTON FALLS, N.J., June 9, 2025 /PRNewswire/ -- Veritas Veterinary Partners ('Veritas' or the 'Company'), a leading network of specialty and emergency veterinary hospitals, is proud to announce a number of key developments in its strategic growth plan, underscoring its commitment to deliver exceptional care across the country. Veritas is investing in new leadership, expanding its national footprint with cutting-edge facilities and accelerating its recruitment of top-tier specialty Doctor of Veterinary Medicine (DVM) talent. To drive forward the Company's ambitious growth strategy, Veritas has appointed several proven leaders in key positions to build out its already deep bench of senior talent. This includes strengthening the role of Veritas Founder and Chief Medical Officer, Dr. Thomas D. Scavelli, DVM, Diplomate ACVS and welcoming four new senior team members: CEO Kenny Gardner, COO Stu Bachelder, CFO Elizabeth Simmons, and CHRO Nikki Rogers. Each brings an impressive track record in human health care, veterinary medicine, retail and operations. Gardner, Bachelder and Rogers previously held senior leadership positions at DaVita Kidney Care, a comprehensive kidney care provider, while Simmons most recently served as CFO of the Arizona College of Nursing. Over the last two years, Veritas has invested significantly in enhancing and expanding its network of hospitals across the U.S. Earlier this year, Veritas opened two new, cutting-edge facilities in Tustin and San Rafael, Calif. The 10,000-square-foot, surgery-focused Tustin location, operated by Veterinary Surgical Specialists of Orange County, is designed to elevate the standard of care through features like a 128-slice CT scan machine and five surgical suites and more. The 28,000-square-foot San Rafael location, operated by Pet Emergency and Specialty Center of Marin, features a state-of-the-art intensive care unit, a chemotherapy treatment suite and other specialized services designed to manage complex and critical cases. In addition, Veritas has opened five satellite emergency hospitals – two in the greater Denver area and three in northern New Jersey with more to come. In parallel, Veritas continues to prioritize the recruitment of specialized DVM talent nationwide. By attracting board-certified specialists and highly skilled veterinarians, the company is strengthening its ability to offer advanced care in areas such as surgery, oncology, cardiology, neurology, critical care, internal medicine and other specialties. 'We've made incredible investments across our business over the past year, and this marks the most exciting period in Veritas's history,' said Veritas CEO Kenny Gardner. 'The strides we've made in our strategic growth plan this year not only reflect our forward-looking perspective and vision, but also signal our long-term commitment to expanding access to the highest standard of veterinary care nationwide.' Veritas invites the public to learn more about its evolution and mission by visiting its newly redesigned website at Since its founding in 2021, Veritas has grown from one referral network into a respected network of nearly 200 specialist and emergency DVMs known for exceptional, personalized, hands-on care. About Veritas Veterinary Partners Veritas Veterinary Partners is a national network of leading specialty and emergency veterinary care hospitals. Built around the principles of truth and trust, Veritas is a mission- and values-driven entity with a network of like-minded partners. By offering extensive resources and access to a national network of leading providers, Veritas enhances growth, recruitment, professional development, and internal culture for its employees. For more information on partnership and career opportunities, please visit Media Contact: Lauren Mueller Director of Communications and Employer Branding [email protected] (262) 352-4656 View original content: SOURCE Veritas Veterinary Partners
Fast Company
an hour ago
- Fast Company
MAHA v. Moderna: The COVID vaccine maker is under attack by RFK Jr.'s department of health
Moderna CEO and cofounder Stéphane Bancel probably never imagined he'd look back on March 2023 as the good old days. Then, he merely had to go before the Senate Health, Education, Labor, and Pensions Committee and take a spitty dressing-down from Senator Bernie Sanders over the price of Moderna's COVID vaccine. The company was held up as a poster child for 'corporate greed.' For a U.S. pharma executive, though, that was more or less business as usual. Today, the situation is anything but. With the confirmation of Robert F. Kennedy Jr., a prominent anti-vaxxer, to be the secretary of the Department of Health and Human Services this February, once-fringe medical theories have been escalated to the level of policy, throwing established scientific and regulatory norms into doubt. Among drugmakers, perhaps none is worse situated to absorb the D.C. vibe shift than Moderna, which is now being targeted not for its pricing but for its one and only product: mRNA-based vaccines. Kennedy has shown a particular distaste for mRNA vaccines, such as those that were rapidly developed by Moderna and Pfizer-BioNTech in response to the global outbreak of COVID-19. During the height of the pandemic, Kennedy petitioned the Food and Drug Administration to revoke authorization for COVID-19 vaccines and not approve any future ones, saying that the risks of adverse reactions and death weren't adequately studied. These vaccines—which have been safely administered to billions of people around the world and in 2021 alone saved at least an estimated 14.4 million lives worldwide—have been the subject of conspiracy theories and misinformation since they were first authorized for emergency use in late 2020. Among the debunked claims of critics: the vaccines can alter a person's genome; they contain microchips or tracking devices; They cause something dubbed turbo cancer. Several states, including Florida, Kentucky, South Carolina, Idaho, and Texas are considering laws that would severely limit or ban the use of mRNA vaccines. Louisiana and Texas have already ended mass vaccinations and any promotion of the vaccines. Now, Kennedy's HHS is taking action against Moderna's signature product. In the past month alone, the CDC has revised its public health recommendations for COVID-19 vaccines, the FDA altered its vaccine approval process, and the government canceled a $766 million contract with Moderna to develop new vaccines against pandemic threats including H5N1 avian influenza. Taken together, these moves have effectively knee-capped Moderna's business. They've also jeopardized public health, and spread uncertainty across the burgeoning landscape of next-generation RNA-based therapeutics. The extended deadline for Fast Company's Brands That Matter Awards is this Friday, June 6, at 11:59 p.m. PT. Apply today.
